SLC5A2 and type 2 diabetes mellitus: Sodium-glucose co-transporter (SGLT2) inhibitors are oral medications that are used to treat hyperglycemia in type 2 diabetes by blocking reabsorption of glucose in the renal proximal tubules, thereby promoting urinary glucose excretion [11, 12].